EXPLORING INCRETIN-BASED THERAPY

Ben W. Seale, M.D. Endocrinology

The Diabetes and Endocrine Center of Mississippi


St. Dominic's Hospital

and the (seilden & press FARM & WINE BAR IT LOUDINY Blue + Cueen bet o mainorited Pink + Pourt C MUSHROO Microsteens A 013 + oukigs CLERONESE Mixed Bras Cherokee 1 Red Tar Meri нловор exO Begu el odmeM Caraflex Hunsan Sugar Rush AROUNI


Disclosures

- I currently speak on behalf of:
 - Abbvie
 Lilly
 NovoNordisk

The Multifactorial Pathophysiology of Type 2 Diabetes Is a Key Factor for Optimizing Individualization of Therapy¹⁻²



GLP-1 and GIP are signals from the gut that reflect the fed state.



*P<0.05 vs oral glucose.1


IV=intravenous.

1. Nauck MA, et al. Diabetes Obes Metab. 2018;20(suppl 1):5-21. 2. Nauck MA, et al. Diabetes. 2019;68(5):897-900.



Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer, throughout this deck, the Full Prescribing Information, and Medication Guide in the participant guide.

Relative contributions of GLP-1 and GIP to the Incretin Effect.^{1,2}




*P<0.05 vs oral glucose.1

IV=intravenous.

1. Nauck MA, et al. Diabetes Obes Metab. 2018;20(suppl 1):5-21. 2. Nauck MA, et al. Diabetes. 2019;68(5):897-900.

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer, throughout this deck, the Full Prescribing Information, and Medication Guide in the participant guide.

T2D IS A PROGRESSIVE INSULIN SECRETORY DEFECT AGAINST THE BACKGROUND OF INSULIN RESISTANCE^{1-3,*}



*Representative depiction of the natural history of T2D highlighting the role of insulin resistance, insulin deficiency, and impaired incretin effect. Both the time course and relative function are descriptive.

T2D=type 2 diabetes.

Kendall DM, et al. Am J Med. 2009;122(suppl 6A):S37-S50.
 Esser N, et al. Diabetologia. 2020;63(10):2007-2021.
 Skyler JS, et al. Diabetes. 2017;66(2):241-255.

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer, throughout this deck, the Full Prescribing Information, and Medication Guide in the participant guide.

John Brown, PhD DSc, FRSC Department of Cellular and Physiological Sciences University of British Columbia





Isolated around 1970
"Gastric Inhibitory Polypetide"
Decrease in stomach acid production

Later re-named, keeping GIP acronym

Glucose-dependent Insulinotropic Polypeptide

Holst and Habener





Jans Juus Holst, MD, DMSc

University of Copenhagen Biomedical Sciences **Joel Francis Habener, MD**

Professor of Medicine Harvard Medical School

Director of Molecular Endocrinology Massachusetts General Hospital



Simultaneously isolated in 1986

Glucagon-like Peptide 1"

Accentuation of beta cell production of insulin

Delay in gastric emptying

Satiety effect realized around 1996

John Eng, MD Department of Endocrinology Veteran's Affairs Mount Sinai Hospital Bronx, NY





Isolated in 1990

Similar in structure and function to GLP-1

Present in venom of various reptiles

Isolated from saliva of Heloderma suspectum





Gila monster



H. suspectum - normal glucose's while fasting

Exposure to animals increased beta cell mass

1999 - daily injection normalized glucose in diabetic mice

Increased insulin production in humans

Longer-acting than endogenous GLP-1


2005 - FDA approval of Exenatide






- Treatment of T2DM
- BID dosing
- Very rapid-acting

GLP-1



GLP=glucagon-like peptide. Adapted from Rachman J et al. *Diabetologia*. 1997;40(2):205-211.

GLP-1



Liraglutide

Analog of endogenous GLP-1

Modified to resist degradation by DPP-4

Daily dosing (half-life 13hrs)

1996 - Invented (NovoNordisk)

2010 - Approval for adult use (T2DM)

2019 - Approval for pediatric use (T2DM)

Liraglutide



- Treatment of T2DM
- Daily dosing
- Longer-acting




Exenatide bound to subcutaneous microspheres

First agent for weekly dosing


Steady-state reached in 6-10 weeks

2014 - FDA approval of Bydureon (adults with T2DM)


Exenatide




Subcutaneous injection



Microsphere aggregation



Microsphere degradation



Continued release









Exenatide



Dulaglutide

GLP-1 analogue resistant to DPP-4 degradation

Bound to FC portion of IgG4 molecule

Does not cross blood-brain barrier

Weekly dosing (half-life 5 days)

2014 - FDA approval of Trulicity (adults with T2DM)



Dulaglutide



Semaglutide

- GLP-1 analogue resistant to DPP-4 degradation
- Bound to albumin
- Can cross blood-brain barrier
- Weekly dosing (half-life 7 days)
- 2017 FDA approval of Ozempic (adults with T2DM)
- NovoNordisk





Tirzepatide

GIP analoge that agonizes both GLP-1-R and GIP-R

Bound to albumin

Can cross blood-brain barrier

Weekly dosing (half-life 5 days)

2022 - FDA approval of Mounjaro (adults with T2DM)



Terzepatide



Treatment of Diabetes Mellitus										
GOALS OF TRE	ATMENT	E								
 Diabetic Goals: 	<u>ADA</u>	<u>ACE</u>								
A1c: Preprandial: Postprandial:	< 7% 70-130 < 180	< 6.5% < 110 < 140								

How aggressive should we be?

- Age
- Risk of hypoglycemia
 Pre-existing cardiovascular disease burden
- Does the drug impact CV risk ?

Diabetes Mellitus and CVD

Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with **XXX** or any other antidiabetic drug.



American Diabetes Association/EASD general therapy recommendations in type 2 diabetes¹

									diabetes ed		
notherapy				Met	formin						
Efficacy				high							
Hypo risk	low risk neutral / loss GI / lactic acidosis										
Weight Side effects											
Costs				low							
	IHbh _{rg} leget not achieved aller-Oranitis of manohempy: proceed a 2d ug combination (adernatives nitiodende any specific preferencechalced ependent anavarday of patient and discuss specific factors);										
Metformin		Metformin		Metformin		Metformin		Metformin		Metformin	
al therapy*	Sulfonylurea	Thiazolidinedione		DPP-4 inhibitor		SGLT2 inhibitor		GLP-1 receptor agonist		Insulin (basal)	
Efficacy		hiah		intermediate						····· highest ······	
Hypo risk	moderate risk	low risk		low risk		low risk		low risk		high risk	
Weight Side effects	gain	gain		neutral		loss		loss		gain	
Costs	hypoglycemia	edema, HF, fxs		high-		GU, dehydration		high		······ hypoglycemia ······	
*Consider initial therapy at this stage			y, poceedta3drug.combination (adernat mea						nespecific factors):		
when HbA _{1c} is ≥9% (≥75 mmol/mol).	Metformin	Metformin		Metformin		∯etformin		Metformin		Metformin	
ple therapy	Sulfonylurea	ea Thiazolidinedione		DPP-4 inhibitor		SGLT2 inhibitor		GLP-1 receptor agonist		Insulin (basal)	
	TZD		SU		SU		SU		SU		TZD
	000.41		DPP-4-i		TZD		TZD		TZD		DPP-4-i
	0/	or		or		or		or		or	
+	or SGLT2-i	or	SGLT2-i	or	SGLT2-i	or	DPP-4-i	or	Insulin [§]	or	SGLT2-i
while all an inite datable discussed	or GLP-1-RA	or	GLP-1-RA	or	Insulin [§]	or	Insulin [§]			or	GLP-1-RA
ombination injectable therapy⁺	or Insulin [§]	or	Insulin [§]								
der initial therapy at this stage when blood e is ≥300-350 mg/dL (≥16.7-19.4 mmol/L)	IH	A _{rc} targetno	tachievedater~3monhsor insulin_add	fripleherapyz GLP-1-RA/	nd paient (1) on orai comb or mealtime insulin. In	ination, move to i	injectables(2) on GLP-1	-RA, addbasal in	rsulin;or(3)on optimally finate au mous	dbasal	
$HbA_{1c} \ge 10-12\% (\ge 86-108 \text{ mmol/mol}),$			mount, add	GEFFINA			sterits consider add	ing 120 01 04	36121.		
ally if patient is symptomatic or if catabolic					Met	ormin					
			D . 1			+	-				
s (weight loss, ketosis) are present, in case basal insulin + mealtime insulin is the			Basal	insulin	+ Mealtin	ne insulin	or	GLP-1-RA			


Trulicity® has not been studied in combination with basal insulin.

[§]Usually a basal insulin (eg, NPH, glargine, detemir, degludec).

HbA1c=glycated hemoglobin; DPP-4-i=dipeptidase-4 inhibitor; EASD=European Association for the Study of Diabetes; fxs=fractures; GU=genitourinary infections; HF=heart failure; SU=sulfonylurea; TD=thiazolidinedione. 1. Inzucchi SE, et al. Diabetes Care, 2015;38(1):140-149.

Glycemic Control Algorithm





PROGRESSION OF DISEASE

Incretin Receptor Agonists










Safety Considerations with GLP-1 RA's

GI adverse events	•	Common Usually dose dependent and transient Usually reduced with dose titration
Pancreatitis	•	Pancreatitis has been reported with postmarketing use of some of incretin agents, although no causal relationship has been established Extensive review by FDA of studies involving >80,000 patients has not uncovered reliable evidence of increased pancreatic risk with incretins vs other agents Labeling for all incretins states these agents should be immediately discontinued if pancreatitis is suspected Labeling for GLP-1 receptor agonists suggests consideration of other therapies for patients with a history of pancreatitis
Pancreatic cancer	•	Extensive review by FDA of studies involving >80,000 patients has not uncovered reliable evidence of increased pancreatic risk with incretins vs other agents Further assessments required from long duration-controlled studies or epidemiological databases
Medullary thyroid cancer	•	 Animal data showed an increased incidence of C-cell tumors with liraglutide and exenatide ER treatment, but confirmatory population studies are lacking Labeling for liraglutide and exenatide ER: Patients should be counseled regarding medullary thyroid carcinoma and the signs/symptoms of thyroid tumors Contraindicated in patients with personal/family history of MTC or multiple endocrine neoplasia syndrome type 2
Renal impairment	•	Renal Impairment has been reported postmarketing, usually in association with nausea, vomiting, diarrhea, or dehydration. Use caution when initiating or escalating doses in patients with renal impairment. Exenatide is contraindicated in patients with severe renal insufficiency or ESRD

Glucose Reduction



Nauck MA, et al. *Int J Clin Pract.* 2009;63:46-55. 2. Taskinen MR, et al. *Diabetes Obes Metab.* 2011;13:65-74. 3. DeFronzo RA, et al. *Diabetes Care.* 2009;32:1649-1655. 4. Charbonnel B, et al. *Diabetes Care.* 2006;29:2638-2643. 5. Ahrén B, et al. *Diabetes Care.* 2014;37:2141-2148.
 Dungan KM, et al. *Lancet.* 2014;384:1349-1357. 7. DeFronzo RA et al. *Diabetes Care.* 2005;28:1092-1100.
 Bergenstal RM, et al. *Lancet.* 2010;376:431-439. 9. Pratley RE, et al. *Lancet.* 2010;375:1447-1456. 10.
 Cefalu WT, et al. *Lancet.* 2013;382:941-950. 11. Nauck MA, et al. *Diabetes Care.* 2011;34:2015-2022. 12.
 Haring HU, et al. *Diabetes Care.* 2014;37:1650-1659.




The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, M.D., Christoph Wanner, M.D., John M. Lachin, Sc.D., David Fitchett, M.D., Erich Bluhmki, Ph.D., Stefan Hantel, Ph.D., Michaela Mattheus, Dipl. Biomath., Theresa Devins, Dr.P.H.,
Odd Erik Johansen, M.D., Ph.D., Hans J. Woerle, M.D., Uli C. Broedl, M.D., and Silvio E. Inzucchi, M.D., for the EMPA-REG OUTCOME Investigators Figure 1. The cumulative incidence of death from cardiovascular causes in the empagliflozin group versus placebo group in the EMPA-REG OUTCOME



Hazard ratios (HR) are based on Cox regression analysis. Reproduced with permission from ref 2.

INDICATIONS AND LIMITATIONS OF USE

JARDIANCE is indicated to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus and established CV disease.

LEADER Trial

ORIGINAL ARTICLE


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso, M.D., Gilbert H. Daniels, M.D., Kirstine Brown-Frandsen, M.D., Peter Kristensen, M.D., E.M.B.A., Johannes F.E. Mann, M.D., Michael A. Nauck, M.D., Steven E. Nissen, M.D., Stuart Pocock, Ph.D., Neil R. Poulter, F.Med.Sci., Lasse S. Ravn, M.D., Ph.D., William M. Steinberg, M.D., Mette Stockner, M.D., Bernard Zinman, M.D., Richard M. Bergenstal, M.D., and John B. Buse, M.D., Ph.D., for the LEADER Steering Committee on behalf of the LEADER Trial Investigators*


ABSTRACT



Figure 1. Cumulative incidence of death from cardiovascular causes in the liraglutide group versus placebo group in the LEADER study



Hazard ratios [HR (95%CI)] based on Cox regression analysis Adapted from reference 6



- as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- as an adjunct to standard treatment of cardiovascular risk factors to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and high cardiovascular risk.'

SUSTAIN-6

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Steven P. Marso, M.D., Stephen C. Bain, M.D., Agostino Consoli, M.D., Freddy G. Eliaschewitz, M.D., Esteban Jódar, M.D., Lawrence A. Leiter, M.D., Ildiko Lingvay, M.D., M.P.H., M.S.C.S., Julio Rosenstock, M.D., Jochen Seufert, M.D., Ph.D., Mark L. Warren, M.D., Vincent Woo, M.D., Oluf Hansen, M.Sc., Anders G. Holst, M.D., Ph.D., Jonas Pettersson, M.D., Ph.D., and Tina Vilsbøll, M.D., D.M.Sc., for the SUSTAIN-6 Investigators*

SUSTAIN-6





Figure 1. Cardiovascular Outcomes.

Shown are Kaplan-Meier plots of the primary outcome (a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) (Panel A), nonfatal myocardial infarction (Panel B), nonfatal stroke (Panel C), and death from cardiovascular causes (Panel D). The trial included a planned observation period of 109 weeks for all patients (a 104-week treatment period with a 5-week follow-up period). In Panel C, there were no events in the semaglutide group after week 104. Insets show the same data on an expanded y axis.

 to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease (1).

REWIND




REWIND

TRULICITY CV OUTCOME TRIAL



PRIMARY MACE 3 RESULT


Dulaglutide significantly reduced the risk of Major Adverse Cardiovascular Events (MACE 3: CV death, non-fatal MI or non-fatal stroke) **by 12% vs. placebo**



Gerstein et al. Lancet 2019.


CV OUTCOMES

Consistent effect across three components of MACE, greatest difference observed in Nonfatal Stroke



• To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Incretins for Weight Loss ?









From your Watch later playlist



Semaglutide, Kardashians, and Female Body Image

PowerfulJRE · 2M views · 7 months ago









New York Post



Ozempic patients are getting filler to fix their saggy skin: Ki...

Visit

•

X

Images may be subject to convright I earn More

How did we get here? OZEMPIC FACE????



Incretins for Weight Loss


Saxenda (liraglutide)

Wegovy (semaglutide)


Zepbound (tirzepatide)

Saxenda (liragulitide)

Observed mean change in body weight from baseline




Wegovy (semaglutide)




Zepbound (terzepatide)

A Percent change in body weight (week 0-88)




MOUNJARO 5 MG, 10 MG, AND 15 MG VS <u>OZEMPIC</u> 1 MG AS THE ONLY ADD-ON TO METFORMIN^{1,2}




PATIENTS TAKING MOUNJARO HAD WEIGHT REDUCTIONS THAT CONTINUED THROUGH 40 WEEKS^{1-3,*,†}

Observed mean weight change over time from baseline to 40 weeks1-3,†

Mean baseline weight: Mounjaro 5 mg, 203.9 lb; Mounjaro 10 mg, 209.1 lb; Mounjaro 15 mg, 206.8 lb; Ozempic 1 mg, 206.6 lb



But there is more !



FDA approves Wegovy for CVD reduction in non-diabetic patients

FDA NEWS RELEASE

FDA Approves First Treatment to Reduce Risk of Serious Heart **Problems** Specifically in Adults with Obesity or Overweight

March, 2024



The NEW ENGLAND JOURNAL of MEDICINE

f 💥 in 🖂

PUBLICATIONS V


AUTHOR CENTER


Q


Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

Authors: Vlado Perkovic, M.B., B.S., Ph.D., Katherine R. Tuttle, M.D. ^(D), Peter Rossing, M.D., D.M.Sc. ^(D), Kenneth W. Mahaffey, M.D., Johannes F.E. Mann, M.D., George Bakris, M.D. ^(D), Florian M.M. Baeres, M.D., Thomas Idorn, M.D., Ph.D., Heidrun Bosch-Traberg, M.D., Nanna Leonora Lausvig, M.Sc., and Richard Pratley, M.D., for the FLOW Trial Committees and Investigators^{*} Author Info & Affiliations

Published May 24, 2024 | N Engl J Med 2024;391:109-121 | DOI: 10.1056/NEJMoa2403347 | <u>VOL. 391 NO. 2</u> <u>Copyright © 2024</u>







FDA approves Zepbound for treatment of OSA

FDA NEWS RELEASE

FDA Approves First Medication for Obstructive Sleep Apnea

December, 2024

In summary.... Incretin-based therapy has evidence to improve:

Diabetic control
Weight / obesity
CVD risk
Risk of renal events / progression of CKD
Obstructive Sleep Apnea

Additionally Incretin-based therapy has evidence to improve:

A-fib burden Cancer risk NASH / NAFDL CHF Pre-diabetes PCOS Addiction Alcohol use disorder Opiate addiction Smoking Binge-eating

Ongoing incretin-based research:

Alzheimer's DimentiaParkinson's Disease



The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

f in 🗠

Q

Trial of Lixisenatide in Early Parkinson's Disease

Authors: Wassilios G. Meissner, M.D., Ph.D., Philippe Remy, M.D., Ph.D., Caroline Giordana, M.D., David Maltête, M.D., Pascal Derkinderen, M.D., Ph.D., Jean-Luc Houéto, M.D., Mathieu Anheim, M.D., Ph.D., +37, for the LIXIPARK Study Group^{*} Author Info & Affiliations

Published April 3, 2024 | N Engl J Med 2024;390:1176-1185 | DOI: 10.1056/NEJMoa2312323 | <u>VOL. 390 NO. 13</u> Copyright © 2024

DBRPCT, Phase 2

Diagnosis of Parkinson's Disease (<3 years)

Stable med regimen, NO motor complications

Lixisenatide vs. placebo

Primary outcome: Progression of MC @ 12 mo.... Movement Disorder Society–Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability)

Placebo: 3.04 (progression) Lixisenatide: -0.04 (improvement)

QUESTIONS



benseale@yahoo.com